Global Drugs For Coronavirus Infection Market Size By Type (Type I, Type II), By Application (Application I, Application II), By Region, And Segment Forecasts, 2023 to 2032

The Global Drugs for Coronavirus Infection Market was valued at USD 42.5 billion in 2023 and is projected to reach USD 68.9 billion by 2031, growing at a CAGR of 6.3% during the forecast period from 2023 to 2031. The rapid development and approval of antiviral drugs, monoclonal antibodies, and repurposed therapies during the COVID-19 pandemic have significantly expanded the market. While the acute pandemic phase has subsided, continuous research, new drug approvals, and the emergence of new variants continue to fuel demand for COVID-19 therapeutics.

Additionally, government initiatives and funding for pandemic preparedness, stockpiling of antiviral drugs, and investment in long-term COVID-19 treatment solutions contribute to market growth. The demand for effective post-viral syndrome treatments, particularly for Long COVID, is further expanding the scope of this market.

Drivers

1. Ongoing COVID-19 Variants & Long COVID Cases

Even as vaccination rates increase, mutations in the SARS-CoV-2 virus continue to drive infections, sustaining demand for antiviral medications. Additionally, Long COVID, affecting millions globally, requires therapeutic interventions to manage chronic symptoms like fatigue, brain fog, and organ damage.

2. Development of Broad-Spectrum Antivirals

Pharmaceutical companies are shifting towards broad-spectrum antiviral drugs that target multiple respiratory viruses, including coronaviruses and influenza, ensuring sustained demand beyond the pandemic.

3. Increasing Investments in Pandemic Preparedness

Governments and global health organizations, such as the World Health Organization (WHO) and the Biomedical Advanced Research and Development Authority (BARDA), are investing in stockpiling antiviral drugs and funding research for next-generation coronavirus treatments.

Restraints

1. Declining Emergency Demand for COVID-19 Drugs

As the pandemic transitions into an endemic phase, the demand for emergency treatments like remdesivir, molnupiravir, and Paxlovid has slowed down in some regions, particularly in countries with high vaccination coverage.

2. Stringent Drug Approval Regulations

The transition from emergency use authorization (EUA) to full regulatory approval requires extensive clinical trials, slowing down the launch of newer COVID-19 drugs.

3. High Development Costs

The cost of developing novel antiviral treatments and monoclonal antibodies remains high, limiting the entry of smaller biotech companies into the market.

Opportunities

1. Expansion of Antiviral Drug Research

There is a growing interest in broad-spectrum antiviral drugs that could be used for multiple respiratory infections, enhancing preparedness for future pandemics.

2. Increasing Demand for Long COVID Treatments

The rising number of Long COVID patients worldwide has created an urgent need for anti-inflammatory, immunomodulatory, and antiviral drugs to manage prolonged symptoms.

3. Government Stockpiling & Pandemic Preparedness

Countries are building national antiviral stockpiles to prepare for future COVID-19 waves and new pandemics, ensuring steady market demand.

Market by Drug Type Insights

1. Antiviral Drugs

Largest market segment, driven by continued use of remdesivir (Veklury), molnupiravir (Lagevrio), and nirmatrelvir/ritonavir (Paxlovid).

Increasing R&D in pan-coronavirus antiviral therapies is expected to fuel growth.

2. Monoclonal Antibodies

Initially played a major role in COVID-19 treatment but declined due to new variants reducing efficacy.

Future growth is expected from variant-resistant monoclonal antibodies under development.

3. Anti-Inflammatory & Immunomodulatory Drugs

Drugs like dexamethasone and baricitinib continue to be used for severe COVID-19 cases.

Expanding demand for immune-modulating therapies to treat Long COVID.

Market by Distribution Channel Insights

1. Hospital Pharmacies

Dominated the market in 2023, as most severe COVID-19 cases are treated in hospital settings.

Continued demand for IV antivirals and monoclonal antibodies will sustain this segment.

2. Retail & Online Pharmacies

Growing adoption of oral COVID-19 antivirals, such as molnupiravir and Paxlovid, has driven sales in this segment.

Telehealth adoption is further increasing online pharmacy sales.

3. Government & Institutional Procurement

National governments and global organizations procure bulk antiviral drugs for pandemic preparedness and stockpiling.

Expected to remain a steady revenue stream for pharmaceutical companies.

Market by Regional Insights

1. North America

Largest market share in 2023, driven by strong government procurement programs and high healthcare spending.

The U.S. leads in drug development, with key pharmaceutical companies headquartered in the region.

2. Europe

Second-largest market, with strong government-backed research and centralized procurement by the European Medicines Agency (EMA).

Germany, France, and the U.K. are leading consumers of COVID-19 drugs.

3. Asia-Pacific

Fastest-growing region, driven by high population density, emerging COVID-19 variants, and increasing healthcare investments.

China, India, and Japan are major players in both manufacturing and consumption.

4. Latin America & Middle East & Africa

Growth is driven by international aid programs, government initiatives, and increasing healthcare access.

Brazil, South Africa, and the UAE are key emerging markets.

Competitive Scenario

Major pharmaceutical players in the Global Drugs for Coronavirus Infection Market include:

Pfizer Inc. – Leading manufacturer of Paxlovid (nirmatrelvir/ritonavir).

Merck & Co., Inc. – Producer of molnupiravir (Lagevrio).

Gilead Sciences, Inc. – Developer of remdesivir (Veklury).

Regeneron Pharmaceuticals – Formerly supplied monoclonal antibodies, now focusing on next-gen variants.

Eli Lilly and Company – Previously provided bamlanivimab, shifting towards new COVID-19 drug research.

AstraZeneca – Continues to develop broad-spectrum antiviral solutions.

Roche Holding AG – Partnered with Regeneron on monoclonal antibody therapies.

Moderna, Inc. – Expanding into mRNA-based COVID-19 antiviral treatments.

Recent developments include:

2023: Pfizer secured additional government contracts for Paxlovid.

2024: Gilead announced a next-generation remdesivir formulation with enhanced efficacy.

2025: Merck initiated clinical trials for broad-spectrum oral antivirals targeting SARS-CoV-2 and other respiratory viruses.

Scope of Work – Global Drugs for Coronavirus Infection Market